A NEW MILESTONE IN DIAGNOSING SYNUCLEINOPATHIES LIKE PARKINSON’S DISEASE
The Syn-One Test is the first commercially available test of its kind, applying world-class science and carefully honed laboratory techniques to accurately detect and visualize abnormal alpha-synuclein in cutaneous nerve fibers.
What is the Syn-One Test?
The Syn-One Test provides objective pathological evidence to aid in the diagnostic evaluation of patients with clinical features suggestive of a synucleinopathy.
The synucleinopathies encompass a group of neurodegenerative diseases that include:
- Parkinson’s disease
- Dementia with Lewy bodies
- Multiple system atrophy
- Pure autonomic failure
- REM sleep behavior disorder
An abnormal test that identifies phosphorylated synuclein (p-syn) within cutaneous nerves is highly specific for a diagnosis of a synucleinopathy, but cannot distinguish between the synucleinopathies. Physicians should use the results of the Syn-One Test along with other clinical features to help make a more specific diagnosis.
Syn-One Test Advantages
Highly Specific, Highly Sensitive
The core methods of the Syn-One Test have demonstrated >95% sensitivity and >99% specificity* based on internal QI/QA data and data presented by Gibbons et al at the American Academy of Neurology 2020 annual meeting.
The range of specificity was 95-99% across the synucleinopathy subtypes (ie, Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies, and pure autonomic failure).
This high level of accuracy provides physicians and patients with a new tool to help increase the clarity and confidence of a diagnosis and ultimately guide the recommended treatment plan.
*In patients with a clinically established synucleinopathy excluding REM sleep behavior disorder (RBD).
Reimbursement for Syn-One
CND is a Medicare and Tricare participating provider and has in-network contracts with a growing list of commercial health plans and other insurance carriers. Since health benefits may vary amongst programs and plans, CND’s billing team can help determine a patient’s specific benefits coverage before the required skin biopsy procedure for the Syn-One Test is conducted . CND also offers self-pay options for uninsured and underinsured patients as needed.
Clinical Use Cases
Diagnostic Insights That Matter
Diagnosing a neurodegenerative disease like Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy can be challenging.
While many patients present with unmistakable clinical features in advanced disease, the literature suggests that a misdiagnosis can occur 30-50% of the time in earlier stages of a synucleinopathy. This can lead to sub-optimal care recommendations and poor outcomes. As more effective, targeted drug therapies evolve, it will be critical for diagnostic tools to be put into practice as part of more personalized solutions.
How might you consider appropriate use cases for the Syn-One Test to help confirm a diagnosis?
As the diagram illustrates, there is an array of clinical presentations suggestive of different neurological disorders that can be clarified by using the Syn-One Test to detect the presence of phosphorylated synuclein in cutaneous nerve fibers.
Syn-One Test Pathology Report
The Syn-One Test Pathology Report includes a comprehensive, detailed examination of the patient’s pathologic results.
The report includes:
- The patient’s and provider’s information
- A summary of diagnostic conclusions
- A macroscopic review of the specimen and the stains performed
- A microscopic review of the specimen results
- A review of the patient’s unique pathology with patient-specific photographs and individual biopsy results
In addition to performing staining and analysis for phosphorylated synuclein, Syn-One also includes testing for small fiber neuropathy and amyloidosis.